Literature DB >> 25541089

The problems of antibiotic resistance in cystic fibrosis and solutions.

Carla López-Causapé1, Estrella Rojo-Molinero, María D Macià, Antonio Oliver.   

Abstract

Chronic respiratory infection is the main cause of morbidity and mortality in cystic fibrosis (CF) patients. One of the hallmarks of these infections, led by the opportunistic pathogen Pseudomonas aeruginosa, is their long-term (lifelong) persistence despite intensive antimicrobial therapy. Antimicrobial resistance in CF is indeed a multifactorial problem, which includes physiological changes, represented by the transition from the planktonic to the biofilm mode of growth and the acquisition of multiple (antibiotic resistance) adaptive mutations catalyzed by frequent mutator phenotypes. Emerging multidrug-resistant CF pathogens, transmissible epidemic strains and transferable genetic elements (such as those encoding class B carbapenemases) also significantly contribute to this concerning scenario. Strategies directed to combat biofilm growth, prevent the emergence of mutational resistance, promote the development of novel antimicrobial agents against multidrug-resistant strains and implement strict infection control measures are thus needed.

Entities:  

Keywords:  PK/PD parameters; Pseudomonas aeruginosa; biofilms; combined treatment; cystic fibrosis; epidemic strains; hypermutation; infection control; multidrug resistance; sequential treatment

Mesh:

Substances:

Year:  2014        PMID: 25541089     DOI: 10.1586/17476348.2015.995640

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  16 in total

1.  Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Authors:  Gabriel Cabot; Carla López-Causapé; Alain A Ocampo-Sosa; Lea M Sommer; María Ángeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Patrick Plesiat; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

2.  Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model.

Authors:  Irina Sánchez-Diener; Laura Zamorano; Carla López-Causapé; Gabriel Cabot; Xavier Mulet; Carmen Peña; Rosa Del Campo; Rafael Cantón; Antonio Doménech-Sánchez; Luis Martínez-Martínez; Susana C Arcos; Alfonso Navas; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

3.  Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients.

Authors:  Leonie Greipel; Sebastian Fischer; Jens Klockgether; Marie Dorda; Samira Mielke; Lutz Wiehlmann; Nina Cramer; Burkhard Tümmler
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 4.  Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Authors:  Jürgen B Bulitta; Yuanyuan Jiao; Stefanie K Drescher; Antonio Oliver; Arnold Louie; Bartolome Moya; Xun Tao; Mathias Wittau; Brian T Tsuji; Alexandre P Zavascki; Beom Soo Shin; George L Drusano; Fritz Sörgel; Cornelia B Landersdorfer
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

Review 5.  Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.

Authors:  Anjali Y Bhagirath; Yanqi Li; Deepti Somayajula; Maryam Dadashi; Sara Badr; Kangmin Duan
Journal:  BMC Pulm Med       Date:  2016-12-05       Impact factor: 3.317

6.  Heterogeneous Antimicrobial Susceptibility Characteristics in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients.

Authors:  Xuan Qin; Chuan Zhou; Danielle M Zerr; Amanda Adler; Amin Addetia; Shuhua Yuan; Alexander L Greninger
Journal:  mSphere       Date:  2018-03-14       Impact factor: 4.389

7.  Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins.

Authors:  Gabriel Torrens; Isabel M Barceló; Marcelo Pérez-Gallego; Maria Escobar-Salom; Sara Tur-Gracia; Marta Munar-Bestard; María Del Mar González-Nicolau; Yoandy José Cabrera-Venegas; Estefany Nayarith Rigo-Rumbos; Gabriel Cabot; Carla López-Causapé; Estrella Rojo-Molinero; Antonio Oliver; Carlos Juan
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

Review 8.  A new era for people with cystic fibrosis.

Authors:  Marlou C Bierlaagh; Danya Muilwijk; Jeffrey M Beekman; Cornelis K van der Ent
Journal:  Eur J Pediatr       Date:  2021-07-02       Impact factor: 3.183

Review 9.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553

10.  In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.

Authors:  Jeanne B Forrester; Lisa L Steed; Barbara A Santevecchi; Patrick Flume; Gloria E Palmer-Long; John A Bosso
Journal:  Open Forum Infect Dis       Date:  2018-07-02       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.